Stockholm, Sweden Saturday, February 22, 2025, 09:00 Hrs [IST] ...

The European Commission (EC) has approved Biocon Biologics’ Yesintek, an ustekinumab biosimilar referencing Johnson & Johnson’s Stelara, to treat multiple inflammatory diseases.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ...

SWTX reports mixed fourth-quarter 2024 results. Its newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.

Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...

With the robust demand for personalized medicines and the growing adoption of digital technology, the precision medicine ...

NEW YORK CITY, NY / ACCESS Newswire / February 21, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law ...

Tremfya was administered subcutaneously for both induction and maintenance, inducing a clinical response in 65% of moderate to severe UC patients.

The cell and gene therapies in rare disorders market is expected to grow at a significantly high rate during the forecast period (2025–2034) and main ...

The Canadian dollar is plunging against the Swiss franc during trading on Thursday, as the 200-day EMA has shown itself to be ...

The USD/CAD pair gains to near the key resistance of 1.4200 in European trading hours on Friday. The Loonie pair moves higher ...

Q4 2024 Earnings Call Transcript February 20, 2025 Prothena Corporation plc misses on earnings expectations. Reported EPS is ...